Gilead Sciences Inc

1GILD

Company Profile

  • Business description

    Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

  • Contact

    333 Lakeside Drive
    Foster CityCA94404
    USA

    T: +1 650 574-3000

    E: [email protected]

    https://www.gilead.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    17,600

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,398.0058.20-0.69%
CAC 407,770.48176.612.33%
DAX 4023,086.65589.672.62%
Dow JONES (US)41,317.43564.471.39%
FTSE 1008,596.3599.551.17%
HKSE22,504.68385.271.74%
NASDAQ17,977.73266.991.51%
Nikkei 22536,830.69378.391.04%
NZX 50 Index12,352.9225.030.20%
S&P 5005,686.6782.531.47%
S&P/ASX 2008,177.9060.10-0.73%
SSE Composite Index3,279.037.62-0.23%

Market Movers